aTyr Pharma plans new phase 3 trial for lung disease drug

May 11, 2026 4:01 PM

aTyr Pharma Inc. (NASDAQ: ATYR) will proceed with a new Phase 3 study of efzofitimod for pulmonary sarcoidosis following feedback ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found